Evidence map›Paper›PMID 31658643›Full record

ArticleCancers2019

Mesenchymal Cells Support the Oncogenicity and Therapeutic Response of the Hedgehog Pathway in Triple-Negative Breast Cancer.

Ana M Reyes-Ramos, Karla P Ramos-Cruz, Nelson J Rodríguez-Merced, Michelle M Martínez-Montemayor, Nelson D Franqui-Ríos, Jan P Ríos-Grant, Andrea Flores, Gerónimo Maldonado-Martínez, Wandaliz Torres-García, Maribella Domenech

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Regulation of cancer stem cells in triple negative breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ana M Reyes-RamosDepartment of Chemical Engineering, Universidad de Puerto Rico-Mayagüez, Mayagüez, PR 00680, USA. anamilena.reyes@upr.edu.
Karla P Ramos-CruzDepartment of Chemical Engineering, Universidad de Puerto Rico-Mayagüez, Mayagüez, PR 00680, USA. karlapr2@illinois.edu.
Nelson J Rodríguez-MercedDepartment of Chemical Engineering, Universidad de Puerto Rico-Mayagüez, Mayagüez, PR 00680, USA. nelson.rodriguez20@upr.edu.
Michelle M Martínez-MontemayorDepartment of Biochemistry, Universidad Central del Caribe, School of Medicine-Bayamón, Bayamón, PR 00956, USA. michelle.martinez@uccaribe.edu.ORCID 0000-0002-6933-9905
Nelson D Franqui-RíosIndustrial Biotechnology Program, Universidad de Puerto Rico-Mayagüez, Mayagüez, PR 00680, USA. nelson.franqui@upr.edu.ORCID 0000-0001-8275-7741
Jan P Ríos-GrantIndustrial Biotechnology Program, Universidad de Puerto Rico-Mayagüez, Mayagüez, PR 00680, USA. jan.rios2@upr.edu.
Andrea FloresIndustrial Biotechnology Program, Universidad de Puerto Rico-Mayagüez, Mayagüez, PR 00680, USA. andrea.flores2@upr.edu.
Gerónimo Maldonado-MartínezData Management and Statistical Research Support Unit, Universidad Central del Caribe, School of Medicine-Bayamón, Bayamón, PR 00956, USA. geronimo.maldonado@uccaribe.edu.
Wandaliz Torres-GarcíaDepartment of Industrial Engineering, Universidad de Puerto Rico-Mayagüez, Mayagüez, PR 00680, USA. wandaliz.torres@upr.edu.
Maribella DomenechDepartment of Chemical Engineering, Universidad de Puerto Rico-Mayagüez, Mayagüez, PR 00680, USA. maribella.domenech@upr.edu.ORCID 0000-0001-7061-8090
University of Puerto Rico-Mayaguez · PRCentral University of the Caribbean · PR

Funding

UNIVERSIDAD CENTRAL DEL CARIBE BIOMEDICAL RESEARCH CENTERSG12MD007583 · NIMHD · UNIVERSIDAD CENTRAL DEL CARIBE · PI RODRIGUEZ, JOSE GINEL · 2012 to 2016
$8.4M
RISE: Enhancing Biomedical Achievement in Science and Engineering (RISE-EBASE)R25GM127191 · NIGMS · UNIVERSITY OF PUERTO RICO MAYAGUEZ · PI CASTRO, MIGUEL E · 2018 to 2022
$1.4M
Sensitization of breast cancer and cancer stem cell to systemic therapy by ReishiSC3GM111171 · NIGMS · UNIVERSIDAD CENTRAL DEL CARIBE · PI MARTINEZ, MICHELLE M · 2014 to 2019
$461k
A tumor-mesenchymal in vitro model of Hedgehog signaling in triple negative breasK01CA188167 · NCI · UNIVERSITY OF PUERTO RICO MAYAGUEZ · PI DOMENECH, MARIBELLA · 2014 to 2017
$455k
National Science Foundation NSF-CREST1345156NCI NIH HHS K01 CA188167NIGMS NIH HHS R25 GM127191NIGMS NIH HHS SC3 GM111171NIH HHS 1K01CA188167NIH HHS G12MD007583NIH HHS R25GM127191NIH HHS SC3GM111171Puerto Rico Science and Technology Research Trust 2016-00064B
6 · The paper itself

Abstract

The paracrine interaction between tumor cells and adjacent stroma has been associated with the oncogenic activity of the Hedgehog (Hh) pathway in triple-negative breast tumors. The present study developed a model of paracrine Hh signaling and examined the impact of mesenchymal cell sources and culture modalities in the oncogenicity of the Hh pathway in breast tumor cells. Studies consisted of tumor cell monocultures and co-cultures with cancer-associated and normal fibroblasts, tumor cells that undergo epithelial-mesenchymal transition (EMT), or adipose-derived mesenchymal stem cells (ADMSCs). Hh ligand and pathway inhibitors, GANT61 and NVP-LDE225 (NVP), were evaluated in both cell cultures and a mouse xenograft model. Results in monocultures show that tumor cell viability and Hh transcriptional activity were not affected by Hh inhibitors. In co-cultures, down-regulation of

Indexed as

CAFsEMTHedgehog signalingmesenchymetriple-negative breast cancertumor microenvironment

Identifiers

PMID31658643
PMCPMC6826628
OpenAlexW2979719147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.